Haizheng Pharmaceutical announced that its participating subsidiary Zhejiang Borui Biopharmaceutical Co., Ltd. has submitted an application to the Hong Kong Stock Exchange for the initial public offering of overseas shares and listing on the main board of the Hong Kong Stock Exchange, and has posted the application information on the Hong Kong Stock Exchange website. vRui Biotech is a leading domestic biopharmaceutical company focusing on immunotherapy, and Haizheng Pharmaceutical holds 39.62% of its shares. vRui Biotech's current offering is subject to approval, approval, or filing from relevant regulators and stock exchanges, and there is uncertainty.

Zhitongcaijing · 5d ago
Haizheng Pharmaceutical announced that its participating subsidiary Zhejiang Borui Biopharmaceutical Co., Ltd. has submitted an application to the Hong Kong Stock Exchange for the initial public offering of overseas shares and listing on the main board of the Hong Kong Stock Exchange, and has posted the application information on the Hong Kong Stock Exchange website. vRui Biotech is a leading domestic biopharmaceutical company focusing on immunotherapy, and Haizheng Pharmaceutical holds 39.62% of its shares. vRui Biotech's current offering is subject to approval, approval, or filing from relevant regulators and stock exchanges, and there is uncertainty.